[Interruption of biological drugs in patients affected with inflammatory diseases]

Duodecim. 2016;132(4):369-76.
[Article in Finnish]

Abstract

The use of biological drugs in the treatment of inflammatory rheumatic diseases, bowel diseases, and psoriasis has increased. Patients receiving a biological drug are invariably under the supervision of a specialized physician, but many are also attending basic healthcare clinics. Every physician taking care of a patient receiving a biological drug should be aware of the principles of interruption. In the present article we will focus on common situations, where an interruption of a biological drug must be considered in the treatment of these inflammatory diseases.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Biological Products / administration & dosage*
  • Biological Therapy*
  • Humans
  • Inflammation / drug therapy*
  • Inflammatory Bowel Diseases / drug therapy*
  • Psoriasis / drug therapy*
  • Rheumatic Diseases / drug therapy*

Substances

  • Biological Products